ProMIS Neurosciences is a development-stage biotechnology company headquartered in Toronto, Ontario, and Cambridge, Massachusetts. The company is dedicated to the discovery and development of therapeutic antibodies specifically designed to target toxic oligomers associated with the progression and development of neurodegenerative diseases and other conditions linked to misfolded proteins.

Utilising their proprietary target discovery engine, ProMIS Neurosciences has the capability to predict novel targets referred to as Disease Specific Epitopes (DSEs). These DSEs are identified on the molecular surface of misfolded proteins that play a role in the pathogenesis of neurodegenerative diseases and other disorders characterised by protein misfolding. Notable examples of such diseases include Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS).